---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-025241"
form_type: "8-K"
ticker: null
cik: "0001403708"
company_name: "Evoke Pharma Inc"
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T05:41:32.917532+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Evoke Pharma appoints Greg Pyszcymuka to board as Class I director

## Summary
- Appointed effective Feb 20, 2025; term expires at 2026 annual meeting.
- He is CCO of Aytu Biopharma (Nasdaq: AYTU); appointed under Nantahala Capital Management agreement (Sept 2024).
- Received options for 5,833 shares vesting equally over three years; also standard cash compensation.
- Compensation Committee: Hill (chair), Pyszcymuka, Brady; Nominating & Governance: Pyszcymuka, Widder, Hill (chair).

## SEC filing metadata
- accession: 0000950170-25-025241
- form_type: 8-K
- cik: 0001403708
- company_name: Evoke Pharma Inc
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1403708/000095017025025241/0000950170-25-025241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1403708/000095017025025241/evok-20250220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-025241
- JSON: https://secwatch.observer/filing/0000950170-25-025241.json
- Plain text: https://secwatch.observer/filing/0000950170-25-025241.txt

## Key facts
- Executive change
  Greg Pyszcymuka was appointed as Class I director at Evoke Pharma Inc.
  - Action: appointed
  - Role: Class I director
  source text: On February 20, 2025, pursuant to the amended and restated bylaws of Evoke Pharma, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Greg Pyszcymuka to serve as a Class I director, effective immediately, with an initial term expiring at the Company’s 2026 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1403708/000095017025025241/0000950170-25-025241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.